Ca:Mg Ratio and Cognitive Function
Study Details
Study Description
Brief Summary
Between 2000 and 2015, mortality due to Alzheimer's disease (AD) increased by 123%. No drugs have yet been approved to stop or slow the progression of AD. A delay of five years in the expression of AD would reduce the incidence rate by half. Thus, it is critical to develop novel prevention strategies to delay the onset of this common disease.
As an ancillary study conducted within a precision-based randomized trial (R01CA149633; PI, Dai & Yu]"), the investigators reduced Ca:Mg ratios to 2.3 through 3-month personalized Mg supplementation among those who consumed high Ca:Mg ratio diet, but otherwise in good general health. The investigators test the hypothesis that actively reducing the Ca:Mg ratio among those aged >65 years who consume high Ca:Mg ratio diets improves cognitive function compared to the placebo arm. The investigators further conduct molecular epidemiologic studies to understand the molecular mechanisms.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Active Comparator: GG genotype and magnesium treatment Participants who have the GG genotype will be assigned to magnesium glycinate |
Dietary Supplement: Magnesium glycinate
Oral administration of magnesium glycinate daily for 12 weeks
|
Placebo Comparator: GG genotype and placebo Participants who have the GG genotype will be assigned to placebo group |
Dietary Supplement: Placebo
Oral administration of identical-appearing placebo daily for 12 weeks
|
Active Comparator: GA/AA genotype and magnesium treatment Participants who have the GA/AA genotype will be assigned to magnesium glycinate |
Dietary Supplement: Magnesium glycinate
Oral administration of magnesium glycinate daily for 12 weeks
|
Placebo Comparator: GA/AA genotype and Placebo Participants who have the GA/AA genotype will be assigned to placebo group |
Dietary Supplement: Placebo
Oral administration of identical-appearing placebo daily for 12 weeks
|
Outcome Measures
Primary Outcome Measures
- Cognitive function [12 weeks]
Cognitive function was measured by the Montreal Cognitive Assessment (MoCA)
- APOE Cytosine Modifications [12 weeks]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Participants from our parent study (Personalized Prevention of Colorectal Cancer Trial, NCT#01105169, IRB#100106);
-
Participants who completed the MoCA
Exclusion Criteria:
- Participants did not provide their blood samples in the parent study.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Vanderbilt University Medical Center
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
- 100106a